Posters

Оur experience of intraocular lens power calculation for patients without clinical history with dense cataract after refractive surgery

Poster Details

First Author: N.Lutsenko UKRAINE

Co Author(s):    O. Rudycheva   O. Kravchenko   O. Isakova              

Abstract Details

Purpose:

To assess the accuracy of IOL power calculation using the Rosa and Maloney formula in patients with dense cataracts after refractive surgery without clinical history.

Setting:

Limited Liability Company Vzglyad Medical Centre, Dnipro, Ukraine, State Institution "Zaporizhzhya Medical Academy of Postgraduate Education Ministry of Health of Ukraine"

Methods:

Five eyes of four patients who were underwent cataract phacoemulsification after previous myopic refractive surgery were retrospectively reviewed. . The age of the patients was 39-50 years. All patients had dense cataract, lack of clinical history, axial length measurements were performed by ultrasound method. They were underwent IOL calculation using Rosa and Maloney methods. The K1 and K2 values were calculated mathematically according to the description method and recorded to the ultrasound scanner protocol for IOL calculation. Phacoemulsification was performed by one surgeon, without intraoperative complications. Postoperative refractive results were studied in 1 month.

Results:

The difference between the preoperative target refraction and the actual postoperative manifest refraction was determined in all cases and ranged from +2.0 to -0.5 D. Using the Maloney method for IOL calculation achieved spherical equivalent refraction was +2.0 D in one eye. Using the Rosa method for IOL calculation the achieved spherical equivalent refraction -0.25 D was in 1 eye, -0.5 D – in three eyes. The difference between the calculated refraction and achieved spherical equivalent was ±0.5 D in Rosa method in 80% cases.

Conclusions:

In eyes with previous corneal refractive surgery, dense cataract and absence of clinical history IOL power calculation is very unpredictable. Method Rosa in our cases showed better results where 80% of patients achieved target refraction.

Financial Disclosure:

None